
COMPASS Pathways plc
COMPASS Pathways plc (CMPS) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · CMPS · as of Jun 8, 2026
Key Statistics
Explore COMPASS Pathways plc Data
cmps stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 13 · Buy rate: 92.3%
The CMPS analyst consensus is Buy, based on ratings from 13 Wall Street analysts over the past 3 months. The average 12-month price target is $18.13, representing +49.71% upside from the current price of $12.11.
Competitors & Peers
cmps competitorsStock Performance
Full HistoryAbout COMPASS Pathways plc
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical tri…
what is compass pathways plc · cmps stock overview · compass pathways plc company profile · who is compass pathways plc ceo · cmps NASDAQ · compass pathways plc headquarters · compass pathways plc business segments
About Stock Overview & Key Data
COMPASS Pathways plc (CMPS) is a Healthcare company in the Medical - Care Facilities industry, listed on NASDAQ since Sep 18, 2020. As of the latest trading session, CMPS stock price is $12.11, with a market capitalization of $1.2B. The stock has returned +159.31% over the past 12 months and +75.51% year-to-date.
According to 13 Wall Street analysts, the consensus rating for COMPASS Pathways plc stock is Buy, with an average 12-month price target of $18.13. In fiscal year 2025, COMPASS Pathways plc reported revenue of — and net income of -$287.9M. For detailed data — including COMPASS Pathways plc revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, COMPASS Pathways plc (CMPS) stock price is $12.11. The stock is traded on NASDAQ under the ticker symbol CMPS. The 52-week range is $2.25 – $14.76.